Travere Therapeutics, Inc.
TVTX
$62.12
$0.691.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 33.32% | -1.92% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 33.32% | -1.92% | |||
| Cost of Revenue | -17.10% | 38.79% | |||
| Gross Profit | 130.89% | -37.43% | |||
| SG&A Expenses | 19.76% | -21.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.92% | 1.23% | |||
| Operating Income | 110.71% | -13.84% | |||
| Income Before Tax | 4.69% | -74.33% | |||
| Income Tax Expenses | -70.00% | -113.03% | |||
| Earnings from Continuing Operations | 4.93% | -66.48% | |||
| Earnings from Discontinued Operations | -- | -102.02% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.21% | -1,459.55% | |||
| EBIT | 110.71% | -13.84% | |||
| EBITDA | 169.96% | 18.11% | |||
| EPS Basic | 7.85% | -1,437.42% | |||
| Normalized Basic EPS | 6.33% | -71.33% | |||
| EPS Diluted | 7.85% | -1,437.42% | |||
| Normalized Diluted EPS | 6.33% | -71.33% | |||
| Average Basic Shares Outstanding | 1.75% | 1.74% | |||
| Average Diluted Shares Outstanding | 1.75% | 1.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||